Arcellx

• NCT06626919

  Phase 1, Recruiting, 30 people, 4 Oct 2024

• NCT06413498

  Collaborator, Phase 3, Active, not recruiting, 452 people, 14 May 2024

• Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

  Collaborator, Phase 1, Active, not recruiting, 24 people, 13 Jul 2022

Sources: clinicaltrials.gov